NEWS

WIRES

OTHER

Manhattan Scientifics Files 2009 Year End Results

The company reports several key current items of interest to its 8,500 shareholders. Among the main points are:

• Our Form 10K will report our first significant increase in revenue
• Our projection is to be cash-flow positive in 2010
• Future prospects in our metals business may well exceed plan
• We have initiated our plan to identify an appropriate Fortune 100 industrial partner within the Medical Devices and Big Pharma industries in order to commercialize our Early Cancer Detection Project

CEO Manny Tsoupanarias stated, "Manhattan Scientifics has had a very successful and active year. Our metals business is running well and on-plan. Manhattan Scientific's Metallicum unit is our core business and its Fortune 1000 industrial partner is providing funding sufficient to cover our entire overhead and cost of all operations, presently and into the foreseeable future."

Manhattan Scientifics, Inc., www.mhtx.com, is located in New Mexico, New York, and Montreal. The company's goal is to advance and commercialize disruptive technologies to create profit for its shareholders. It is focused on commercializing disruptive technology in the fields of nanotechnology and nanomedicine.

This press release contains projections of future results and other forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Important factors that may cause actual results and outcomes to differ materially from those contained in the projections and forward-looking statements included in this press release are described in our publicly filed reports. Factors that could cause these differences include, but are not limited to, failure to realize projected revenues and cash flows and market conditions that negatively affect the market for our technology. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Manhattan Scientifics Inc.
Marvin Maslow, Director of Investor Relations, 917-923-3300
marvin@mhtx.com
or
Institutional Investor Relations:
Hawk Associates
Frank Hawkins, 305-451-1888
F.hawkins@hawkassociates.com
Website: http://www.hawkassociates.com